Helus Pharma Inc.

HELPReported to SECin USCIK 0001833141Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 11. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 11
Form 4 lines at Helus Pharma Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
So Eric H. L.—Award—248,000 sharesOct 1, 2026So Eric H. L.—Award · Oct 1Award248,000Oct 1, 2026
Cavers GregChief Financial OfficerOpen-market buy$38,7303,000 sharesOct 1, 2026Cavers GregChief Financial Officer$38,730Buy · Oct 1Open-market buy3,000Oct 1, 2026
Glavine PaulChief Growth OfficerAward—248,000 sharesOct 1, 2026Glavine PaulChief Growth Officer—Award · Oct 1Award248,000Oct 1, 2026
Halstead MichaelChief Executive OfficerOpen-market buy$1,347,050100,000 sharesSep 21, 2026Halstead MichaelChief Executive Officer$1,347,050Buy · Sep 21Open-market buy100,000Sep 21, 2026
Glavine PaulChief Growth OfficerOpen-market buy$1,247,190100,000 sharesSep 11, 2026Glavine PaulChief Growth Officer$1,247,190Buy · Sep 11Open-market buy100,000Sep 11, 2026